Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy

被引：38

作者：

Calmy, A ^{[1
]}

Hirschel, B

Hans, D

Karsegard, VL

Meier, CA

机构：

[1] Hop Cantonal Univ Geneva, Div Infect Dis, Geneva, Switzerland

[2] Hop Cantonal Univ Geneva, Div Nucl Med, Geneva, Switzerland

[3] Hop Cantonal Univ Geneva, Div Endocrinol Diabetol & Nutr, Geneva, Switzerland

来源：

AIDS | 2003年 / 17卷 / 05期

关键词：

D O I：

10.1097/00002030-200303280-00022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Anti-diabetic glitazones are known to alter fat distribution in non-HIV lipodystrophy. We therefore assessed the safety and preliminary efficacy of treatment with pioglitazone for 6 months in 11 patients with lipodystrophy related to highly active antiretroviral therapy (HAART). No serious side-effects were observed. Body fat mass (total and leg) increased significantly, whereas no changes were found in the lipid profile. The good tolerance and fat redistribution observed with pioglitazone warrants a larger randomized trial in patients with HAART-related lipodystrophy.

引用

收藏

页码：770 / 772

页数：3

相关论文

共 11 条

[1] Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes [J].

Arioglu, E ;

Duncan-Morin, J ;

Sebring, N ;

Rother, KI ;

Gottlieb, N ;

Lieberman, J ;

Herion, D ;

Kleiner, DE ;

Reynolds, J ;

Premkumar, A ;

Sumner, AE ;

Hoofnagle, J ;

Reitman, ML ;

Taylor, SI .

ANNALS OF INTERNAL MEDICINE, 2000, 133 (04) :263-274

[2] Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy [J].

Barreiro, P ;

Soriano, V ;

Blanco, F ;

Casimiro, C ;

de la Cruz, JJ ;

González-Lahoz, J .

AIDS, 2000, 14 (07) :807-812

[3] Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance [J].

Bastard, JP ;

Caron, M ;

Vidal, H ;

Jan, V ;

Auclair, M ;

Vigouroux, C ;

Luboinski, J ;

Laville, M ;

Malachi, M ;

Girard, PM ;

Rozenbaum, W ;

Levan, P ;

Capeau, J .

LANCET, 2002, 359 (9311) :1026-1031

[4] The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance [J].

Caron, M ;

Auclair, R ;

Vigouroux, C ;

Glorian, M ;

Forest, C ;

Capeau, J .

DIABETES, 2001, 50 (06) :1378-1388

[5] Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].

Carr, A ;

Samaras, K ;

Thorisdottir, A ;

Kaufmann, GR ;

Chisholm, DJ ;

Cooper, DA .

LANCET, 1999, 353 (9170) :2093-2099

[6]

ENGELHARD P, 2000, 13 INT AIDS C DURB S

[7]

LAFAURIE M, 2002, 9 C RETR OPP INF SEA

[8] Leptin-replacement therapy for lipodystrophy [J].

Oral, EA ;

Simha, V ;

Ruiz, E ;

Andewelt, A ;

Premkumar, A ;

Snell, P ;

Wagner, AJ ;

DePaoli, AM ;

Reitman, ML ;

Taylor, SI ;

Gorden, P ;

Garg, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) :570-578

[9] A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy [J].

Saint-Marc, T ;

Partisani, M ;

Poizot-Martin, I ;

Bruno, F ;

Rouviere, O ;

Lang, JM ;

Gastaut, JA ;

Touraine, JL .

AIDS, 1999, 13 (13) :1659-1667

[10] Clinical perspectives on HIV-associated lipodystrophy syndrome: an update [J].

Shevitz, A ;

Wanke, CA ;

Falutz, J ;

Kotler, DP .

AIDS, 2001, 15 (15) :1917-1930